Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dr. Stephen Spielberg to Host Prominent Professionals at DIA EuroMeeting 2013

Published: Thursday, February 28, 2013
Last Updated: Wednesday, February 27, 2013
Bookmark and Share
DIA Europe’s 25th Annual EuroMeeting to be held in Amsterdam from 4-6 March, 2013.

Dr. Stephen Spielberg, M.D., Ph.D., Editor-in-Chief of DIA’s peer-reviewed scientific journal, Therapeutic Innovation & Regulatory Science (TIRS), will be meeting high-profile industry experts from around the world at DIA Europe’s 25th Annual EuroMeeting in Amsterdam from 4-6 March, 2013.

Dr. Spielberg will welcome EuroMeeting 2013 participants at the DIA’s exhibition booth on Monday 4 March.

Then, on 6 March, a host of prominent industry experts, including representatives from the European Medicines Agency (EMA) and the Directorate General for Health and Consumer Affairs (DG SANCO), will be invited to a meet and greet breakfast and a TIRS Editorial lunch.

Dr. Spielberg said: “I am greatly looking forward to welcoming participants to the EuroMeeting 2013 in Amsterdam. This year promises to be an insightful event with 110 comprehensive sessions.”

More than 300 high-profile speakers, moderators, and panelists from around the world are set to attend EuroMeeting 2013, substantiating the meeting’s claim to being the most important event in the medicines development calendar.

The meeting will feature 200 exhibitors and bring together professionals from the biopharmaceutical industry, contract research and service organizations, academic research centres, health ministries, and delegates from patient organizations to share knowledge focusing on better public health protection, greater transparency of processes, and the rational use of medicinal products.

For more information about the event visit www.diahome.org/EM2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!